Minerva Neurosciences, Inc.
About Minerva Neurosciences, Inc.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$293.4M
- Total assets
- $98.0M
- Market cap
- $231.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $15.1M
- Operating income
- -$15.1M
- Net income
- -$293.4M
- EPS (basic)
- $-34.67
- EPS (diluted)
- $-34.67
Balance sheet
- Total assets
- $98.0M
- Current assets
- $83.1M
- Total liabilities
- $233.8M
- Current liabilities
- $2.3M
- Shareholders’ equity
- -$140.7M
Cash flow
- Operating cash flow
- -$13.5M
- Investing cash flow
- -$60.9M
- Financing cash flow
- $74.5M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $231.1M
- EPS (diluted)
- $-34.67
- Shares outstanding
- 49.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 1, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $293.4M in FY2024.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Minerva Neurosciences, Inc..
Write a review
News about Minerva Neurosciences, Inc.
News & sentiment via Polygon.io
